IL13RA2 and colorectal carcinoma: Based on this, the next steps for this study include validating IL13RA2 overexpression in CR-SRCC over CCC by immunohistochemistry, determining its role in CRC-SRCC pathogenesis, and developing an antibody drug conjugate targeting IL13RA2.